Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pegasys Growth Strategy Will Focus On HIV/HCV Co-Infection And Hepatitis B

This article was originally published in The Pink Sheet Daily

Executive Summary

Roche's pegylated interferon product has captured 52% of total Rxs. APRICOT study in HIV/HCV co-infection shows Pegasys/Copegus (ribavirin) combo therapy yields 40% sustained virologic response.

You may also be interested in...



Roche Pegasys sBLA Filing For Hepatitis B Could Receive Priority Review

Roche announced simultaneous U.S. and European submissions July 21; six-month review would set user fee date at mid-January. Roche is likely to highlight superiority to GlaxoSmithKline’s Epivir-HBV and efficacy in HBeAg-negative patients in promotions.

Madrigal’s FDA Approval In MASH Ends Years Of Industry Frustration

As the first approved MASH (formerly NASH) therapy, nearly four years after initially anticipated, Madrigal gets the opportunity to establish a MASH marketplace with Rezdiffra (resmetirom).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS058608

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel